Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage: Lessons from Chile
dc.contributor.author | Aguilera, Ximena | |
dc.contributor.author | González, Claudia | |
dc.contributor.author | Apablaza, Mauricio | |
dc.contributor.author | Rubilar, Paola | |
dc.contributor.author | Icaza, Gloria | |
dc.contributor.author | Ramírez-Santana, Muriel | |
dc.contributor.author | Pérez, Claudia | |
dc.contributor.author | Cortés, Lina Jimena | |
dc.contributor.author | Núñez-Franz, Loreto | |
dc.contributor.author | Quezada-Gaete, Rubén | |
dc.contributor.author | Castillo-Laborde, Carla | |
dc.contributor.author | Correa, Juan | |
dc.contributor.author | Said, Macarena | |
dc.contributor.author | Hormazábal, Juan | |
dc.contributor.author | Vial, Cecilia | |
dc.contributor.author | Vial, Pablo | |
dc.date.accessioned | 2023-04-27T16:51:21Z | |
dc.date.available | 2023-04-27T16:51:21Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Objective: Chile is among the most successful nations worldwide in COVID-19 vaccine rollout. By December 31st, 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using DIFFERENT TYPES OF COVID-19 VACCINES. In this context, we aimed to estimate the anti-SARSCoV-2 antibodies following the infection and vaccination campaign. Study design: Population-based cross-sectional serosurvey based on a representative sample of the cities of Santiago, Coquimbo/La Serena, and Talca used in a previous study. Methods: We selected the participants using a three-stage stratified sampling. They were blood-sampled on-site and answered a questionnaire regarding COVID-19-associated variables and vaccination antecedents using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. This research followed the generic protocol of World Health Organization Unity studies. Results: We recruited 2,198 individuals aged 7-93 between October 5th and November 25th, 2021. In our sample, 2,132 individuals received COVID-19 vaccinations (97%); 67 (3.1%) received one dose; 2,065 (93.9%) received the complete scheme; and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR=674.6, 154.8-2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. Conclusion: We found a seroprevalence close to 100% in the population aged seven years and older, primarily due to the successful vaccination program, which has a strong emphasis on universal access. | |
dc.description.version | Versión enviada | |
dc.format.extent | 11 p. | |
dc.identifier.citation | Aguilera, X., González, C., Apablaza, M., Rubilar, P., Icaza, G., Ramírez-Santana, M., ... & Vial, P. (2022). Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage: Lessons from Chile. Vaccines, 10(7), 1002 | |
dc.identifier.doi | https://doi.org/10.21203/rs.3.rs-1548211/v2 | |
dc.identifier.uri | https://repositorio.udd.cl/handle/11447/7417 | |
dc.language.iso | en | |
dc.subject | COVID-19, Vaccine coverage, Sinovac CoronaVac, BNT162b2, AZD1222, Ad5-nCoV, cross sectional, population-based, Santiago, Talca, Coquimbo, La Serena, ELISA, sero-survey | |
dc.subject | Vaccine coverage | |
dc.subject | Sinovac CoronaVac | |
dc.subject | BNT162b2 | |
dc.subject | AZD1222 | |
dc.subject | Ad5-nCoV | |
dc.subject | Cross sectional | |
dc.subject | Population-based | |
dc.subject | ELISA | |
dc.subject | Sero-survey | |
dc.subject | Santiago | |
dc.subject | Talca | |
dc.subject | Coquimbo | |
dc.subject | La Serena | |
dc.title | Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage: Lessons from Chile | |
dc.type | Article | |
dcterms.accessRights | Acceso abierto | |
dcterms.source | Vaccines |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage Lessons from Chile.pdf
- Size:
- 438.21 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.63 KB
- Format:
- Item-specific license agreed upon to submission
- Description: